Table of Contents
ISRN Oncology
Volume 2013 (2013), Article ID 252318, 4 pages
Research Article

CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma

1Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, 0310 Oslo, Norway
2Faculty of Medicine, University of Oslo, 0316 Oslo, Norway

Received 16 November 2012; Accepted 11 December 2012

Academic Editors: M. Emoto, N. A. Franken, H. Zhang, and J. M. Zidan

Copyright © 2013 Gunhild Trøen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The mutation status of genes involved in the NF-κB signaling pathway in splenic marginal zone lymphoma was examined. DNA sequence analysis of four genes was performed: CD79A, CD79B, CARD11, and MYD88 that are activated through BCR signaling or Toll-like and interleukin signaling. A single point mutation was detected in the CD79B gene (Y196H) in one of ten SMZL cases. Additionally, one point mutation was identified in the MYD88 gene (L265P) in another SMZL case. No mutations were revealed in CD79A or CARD11 genes in these SMZL cases. Neither were mutations detected in these four genes studied in 13 control MZL samples. Interestingly, the two cases with mutations of CD79B and MYD88 showed increased numbers of immunoblasts spread among the smaller and typical marginal zone lymphoma cells. Although SMZL shows few mutations of NF-κB signaling genes, our results indicate that the presence of these mutations is associated with a higher histological grade.